Exponent, Inc., 3401 Market St, Suite 300, Philadelphia, PA 19104, USA.
Osteoporos Int. 2013 Apr;24(4):1437-45. doi: 10.1007/s00198-012-2100-0. Epub 2012 Aug 8.
The costs for treating kypho- and vertebroplasty patients were evaluated at up to 2 years postsurgery. There were no significant differences in adjusted costs in the first 9 months postsurgery, but kyphoplasty patients were associated with significantly lower adjusted treatment costs by 6.8-7.9% in the remaining periods through 2 years postsurgery.
Vertebral augmentation has been shown to be safe and effective for treating vertebral compression fractures. Comparative cost studies of initial treatment costs for kypho- and vertebroplasty have been mixed. The purpose of our study was to compare the costs for treating kypho- and vertebroplasty patients at up to 2 years postsurgery.
Vertebroplasty and kyphoplasty patients diagnosed with pathologic or closed lumbar/thoracic vertebral fractures were identified from the 5% sample of the Medicare dataset (2006-2009). The final study cohort with at least 2 years follow-up comprised of 1,609 vertebroplasty and 2,878 kyphoplasty patients. The cumulative treatment costs (adjusted to June 2011 US$) were determined from the payer perspective. Differences in costs and length of stay were assessed by generalized linear mixed model regression, adjusting for covariates.
The average adjusted costs for vertebroplasty patients within the first quarter and the first 2 years postsurgery were $14,585 [95% confidence interval (CI), $14,109-15,078] and $44,496 (95% CI, $42,763-46,299), respectively. The corresponding average adjusted costs for kyphoplasty patients were $15,117 (95% CI, $14,752-15,491) and $41,339 (95% CI, $40,154-42,560). There were no significant differences in adjusted costs in the first 9 months postsurgery, but kyphoplasty patients were associated with significantly lower adjusted treatment costs by 6.8-7.9% in the remaining periods through 2 years postsurgery.
Our present study addresses some of the limitations in previous comparative cost studies of vertebroplasty and kyphoplasty. The higher adjusted costs for vertebroplasty patients than kyphoplasty patients by 1 year following the surgery reflect greater utilization of medical resources.
本研究旨在比较经皮椎体后凸成形术(kyphoplasty)和经皮椎体成形术(vertebroplasty)患者在术后 2 年内的治疗成本。
从 Medicare 数据集的 5%样本中(2006-2009 年)确定了病理性或闭合性腰椎/胸椎椎体骨折的椎体成形术和后凸成形术患者。最终的研究队列至少有 2 年的随访时间,包括 1609 例椎体成形术患者和 2878 例后凸成形术患者。从支付者的角度确定了(调整至 2011 年 6 月的美国美元)累积治疗成本。使用广义线性混合模型回归评估成本和住院时间的差异,同时调整协变量。
术后第 1 季度和第 2 年,椎体成形术患者的平均调整后成本分别为$14585[95%置信区间(CI),$14109-15078]和$44496(95%CI,$42763-46299)。后凸成形术患者的相应平均调整后成本分别为$15117(95%CI,$14752-15491)和$41339(95%CI,$40154-42560)。术后前 9 个月,调整后的成本没有显著差异,但在后 2 年的剩余时间里,后凸成形术患者的调整后治疗成本显著降低了 6.8-7.9%。
本研究解决了先前经皮椎体后凸成形术和经皮椎体成形术比较性成本研究中的一些局限性。术后 1 年,椎体成形术患者的调整后成本高于后凸成形术患者,这反映了医疗资源的利用更大。